Although previous research revealed that activation of PI3K-AKT pathway plays a critical role in providing an alternative survival pathway in cancer cells [5–8, 10], the mechanism responsible for the development of resistance to therapeutic drugs in primary and metastatic tumor cells is not fully understood. This evidence concerns the gene AKT1 and metastatic neoplasm.